WASHINGTON
(Reuters) - Children taking Vertex Pharmaceuticals Inc's cystic
fibrosis pill may be at risk of getting cataracts, based on a study in
juvenile rats, according to a statement Wednesday on the U.S. Food and
Drug Administration's website.The FDA added information about
the risk on Wednesday to the label for Kalydeco, the first drug designed
to treat the underlying cause of cystic fibrosis, a life-shortening
genetic disease that impairs the lungs and digestive system and affects
about 30,000 people in the United States.
No comments:
Post a Comment